0001104659-21-127048.txt : 20211018 0001104659-21-127048.hdr.sgml : 20211018 20211018113449 ACCESSION NUMBER: 0001104659-21-127048 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211013 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211018 DATE AS OF CHANGE: 20211018 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arch Therapeutics, Inc. CENTRAL INDEX KEY: 0001537561 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 460524102 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54986 FILM NUMBER: 211327703 BUSINESS ADDRESS: STREET 1: 235 WALNUT STREET, SUITE 6 CITY: FRAMINGHAM STATE: MA ZIP: 01702 BUSINESS PHONE: 617-431-2313 MAIL ADDRESS: STREET 1: 235 WALNUT STREET, SUITE 6 CITY: FRAMINGHAM STATE: MA ZIP: 01702 FORMER COMPANY: FORMER CONFORMED NAME: ALMAH,INC DATE OF NAME CHANGE: 20111216 8-K 1 tm2130392d1_8k.htm FORM 8-K
0001537561 false 0001537561 2021-10-13 2021-10-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 13, 2021

 

ARCH THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   000-54986   46-0524102
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

235 Walnut Street, Suite 6   
Framingham, Massachusetts  01702
(Address of principal executive offices)  (Zip Code)

 

Registrant’s telephone number, including area code: (617) 431-2313

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
N|A N|A N|A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On October 13, 2021, Arch Therapeutics, Inc. (the “Company”) issued a press release announcing its first sale into a Veterans Administration (“VA”) hospital through its distribution partner, Lovell Government Services (“LGS”). The Company also announced other recent developments including, i) continued slowly improving access to its AC5 Advanced Wound System to hospitals, clinics, and other healthcare facilities; ii) inclusion of the AC5 Advanced Wound System on multiple purchasing schedules through LGS necessary to transact business with VA hospitals and other government channel facilities; and iii) launch of the recently announced pilot program.

 

The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

Item 8.01 Other Events.

 

The disclosure under Item 7.01 (Regulation FD Disclosure) is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibit

 

(d) The following exhibits are being filed herewith:

 

Exhibit   Description
99.1   Press Release issued by Arch Therapeutics, Inc. on October 13, 2021.
104   Cover Page Interactive Data File (embedded within the Inline XBRL Document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ARCH THERAPEUTICS, INC.
   
Dated: October 18, 2021 By: /s/ Terrence W. Norchi, M.D.
  Name: Terrence W. Norchi, M.D.
  Title: President, Chief Executive Officer

 

 

 

 

 EX-99.1 2 tm2130392d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

Arch Therapeutics Provides Corporate Update

90-Day Report Card for Commercialization Effort

 

FRAMINGHAM, MA – October 13, 2021 – Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today provided a corporate update at the LD Micro Main Event XIV investor conference in Los Angeles, CA. The presentation slides will be publicly available through the SEC website as an attachment to the Form 8-K filed in connection with this press release as well as on the corporate website at www.ir.archtherapeutics.com/presentations.

 

Among other noted achievements, the Company announced its first sale into a Veterans Administration (“VA”) hospital through its new distribution partner, Lovell Government Services (“LGS”), a respected and recognized Service-Disabled Veteran-Owned Small Business (“SDVOSB”). This milestone, while admittedly a single small step, stems from the continued deployment and execution of the revamped commercialization effort led by new team members, including Dan Yrigoyen, who joined Arch Therapeutics 90-days ago as Head of Sales. Other important recent developments include, i) continued slowly improving access to hospitals, clinics, and other healthcare facilities; ii) inclusion on multiple purchasing schedules through LGS necessary to transact business with VA hospitals and other government channel facilities; and iii) launch of the recently announced pilot program, which represents the critical next step forward in the Company’s non-government go to market strategy.

 

“The progress made in the overall development of the Company’s commercialization plan over the last ninety days has been remarkable. Working together, the new team made steady progress in the execution of our go to market strategy for both the government and commercial channels,” stated Terry Norchi, MD, Chief Executive Officer of Arch Therapeutics. “While early results are expected to be modest, we have cleared some important hurdles. We remain focused on leveraging our new capabilities and initiatives to drive incremental revenue going forward. It is truly an exciting time as we continue to drive our mission to provide superior outcomes to patients, including veterans who struggle with painful and disruptive challenging wounds,” concluded Dr. Norchi.

 

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma, and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.1,2

 

 

1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.

2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

 

 

 

 

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our ability to recruit additional field sales representatives and their effectiveness, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to obtain the inclusion of our AC5® Advanced Wound System on targeted federal supply schedules, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

 

Contact:

ARTH Investor Relations

Toll Free: +1-855-340-ARTH (2784) (US and Canada)

Email: investors@archtherapeutics.com

Website: www.archtherapeutics.com

 

or

 

Michael Abrams

Chief Financial Officer

Arch Therapeutics, Inc.

Phone: 617-431-2333

Email: mabrams@archtherapeutics.com

 

 

 

 EX-101.SCH 3 arth-20211013.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 arth-20211013_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 arth-20211013_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm2130392d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001537561 2021-10-13 2021-10-13 iso4217:USD shares iso4217:USD shares 0001537561 false 8-K 2021-10-13 ARCH THERAPEUTICS, INC. NV 000-54986 46-0524102 235 Walnut Street Suite 6 Framingham MA 01702 617 431-2313 false false false false false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Oct. 13, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 13, 2021
Entity File Number 000-54986
Entity Registrant Name ARCH THERAPEUTICS, INC.
Entity Central Index Key 0001537561
Entity Tax Identification Number 46-0524102
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 235 Walnut Street
Entity Address, Address Line Two Suite 6
Entity Address, City or Town Framingham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01702
City Area Code 617
Local Phone Number 431-2313
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://archtherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2130392d1_8k.htm arth-20211013.xsd arth-20211013_lab.xml arth-20211013_pre.xml tm2130392d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2130392d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2130392d1_8k.htm" ] }, "labelLink": { "local": [ "arth-20211013_lab.xml" ] }, "presentationLink": { "local": [ "arth-20211013_pre.xml" ] }, "schema": { "local": [ "arth-20211013.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "arth", "nsuri": "http://archtherapeutics.com/20211013", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2130392d1_8k.htm", "contextRef": "From2021-10-13to2021-10-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://archtherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2130392d1_8k.htm", "contextRef": "From2021-10-13to2021-10-13", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://archtherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-21-127048-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-127048-xbrl.zip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